Trial · NCT04201093
Results by group222
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 222
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Placebo | 1.8 | Standard Error 0.82 | score on a scale | |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 5 mg | -9.7 | Standard Error 0.86 | score on a scale | |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 15 mg | -10.2 | Standard Error 0.88 | score on a scale | |
| Change From Baseline in the MDS-UPDRS Part II Score | Placebo | 0.9 | Standard Error 0.30 | score on a scale | |
| Change From Baseline in the MDS-UPDRS Part II Score | Tavapadon 5 mg | -1.6 | Standard Error 0.31 | score on a scale | |
| Change From Baseline in the MDS-UPDRS Part II Score | Tavapadon 15 mg | -1.7 | Standard Error 0.32 | score on a scale | |
| Percentage of Responders With a Score of Much Improved or Very Much Improved on PGIC | Placebo | 18 | Participants | ||
| Percentage of Responders With a Score of Much Improved or Very Much Improved on PGIC | Tavapadon 5 mg | 60 | Participants | ||
| Percentage of Responders With a Score of Much Improved or Very Much Improved on PGIC | Tavapadon 15 mg | 52 | Participants | ||
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Placebo | Week 5 | -1.2 | Standard Error 0.57 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 5 mg | Week 5 | -4.4 | Standard Error 0.59 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 15 mg | Week 5 | -4.7 | Standard Error 0.59 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Placebo | Week 8 | -2.2 | Standard Error 0.62 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 5 mg | Week 8 | -6.9 | Standard Error 0.65 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 15 mg | Week 8 | -6.7 | Standard Error 0.65 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Placebo | Week 11 | -0.9 | Standard Error 0.72 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 5 mg | Week 11 | -8.1 | Standard Error 0.75 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 15 mg | Week 11 | -9.1 | Standard Error 0.75 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Placebo | Week 14 | -1.2 | Standard Error 0.74 | score on a scale |
| Change From Baseline in the MDS-UPDRS Parts II and III Combined Score | Tavapadon 5 mg | Week 14 | -8.8 | Standard Error 0.78 | score on a scale |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04201093/results